About Avenue Therapeutics (ATXI)

The current price per share for Avenue Therapeutics (ATXI) is $0.42. The stock has seen a price change of -$0.44 recently, indicating a -51.07% change. This reflects the stock's recent market performance and investor sentiment.

For Avenue Therapeutics (ATXI), the 52-week high is $50.62, which is 11.95K% from the current price. The 52-week low is $0.39, the current price is 6.87% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

Avenue Therapeutics (ATXI) has shown an average price growth of -1.65% over the past three years. It has received a score of 94 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Avenue Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

As of the latest data, Avenue Therapeutics (ATXI) has a year-to-date price change of -79%. Over the past month, the stock has experienced a price change of -58.37%. Over the last three months, the change has been -79.61%. Over the past six months, the figure is -81.9%. Looking at a longer horizon, the five-year price change stands at -100%.

Avenue Therapeutics (ATXI) has a net income of -$10.38M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$14.54M. Furthermore, the EBITDA is $0.

Avenue Therapeutics (ATXI) has a market capitalization of $862.65K. The average daily trading volume is 0.46, indicating the stock's liquidity and investor engagement.